GSK256073|cas:862892-90-8|西域试剂

GSK256073,99.27%

产品编号：Bellancom-119222| CAS NO：862892-90-8| 分子式：C₁₀H₁₃ClN₄O₂| 分子量：256.69

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-119222	￥1800.00	杭州北京（现货）
Bellancom-119222	￥2800.00	杭州北京（现货）
Bellancom-119222	￥4900.00	杭州北京（现货）
Bellancom-119222	￥7500.00	杭州北京（现货）
Bellancom-119222	￥11000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

GSK256073

产品介绍

GSK256073 是一种有效的、选择性的、口服活性的 GPR109A 激动剂，是一种持久的 HCA2 激动剂，其 pEC₅₀ 为 7.5 (Human HCA2)。GSK256073 可通过抑制脂降解而明显改善葡萄糖稳态，具有研究 2 型糖尿病 (T2DM) 和血脂异常的潜力。

生物活性

GSK256073 is a potent, selective and orally active GPR109A agonist and a long-lasting and non-flushing HCA2 full agonist with a pEC₅₀ of 7.5 (human HCA2). GSK256073 acutely improves glucose homeostasis via inhibition of lipolysis and has the potential for the study of type 2 diabetes mellitus (T2DM)and dyslipidemia. GPR109A: G-protein coupled receptor 109A; HCA2: hydroxy-carboxylic acid receptor 2

体外研究

GSK256073 is approximately 10-fold more potent than niacin against human HCA2 (pEC₅₀ value of 7.5 compared to 6.7 for niacin), has good activity versus the rat orthologue of HCA2 (pEC₅₀ value of 6.9 compared to 6.4 for niacin) in membranes prepared from Chinese hamster ovary cellsexpressing recombinant human HCA2.
GSK256073 (100 μM) suppresses cAMP elevation induced by isoprenaline (100 nM) in rat primary adipocytes.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

GSK256073 (oral adminstration; 1, 30 and 100 mg/kg; in rat) shows that the fall in NEFA is of rapid onset and that the maximum is dose-related with inhibitions of 74, 81 and 88%, respectively. Triglycerides decrease is followed as a similar pattern,although the duration was longer with a decrease of 91% still present 6 h post dose at 10 mg/kg.
GSK256073 (intravenous injection; 1-10 mg/kg) produces a dose related decrease in NEFA. However, the increase in ear temperature induced by 10 mg/kg i.v. GSK256073 is only 40% of that induced by 10 mg/kg i.v. niacin.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SD rat
Dosage:	1, 30 and 100 mg/kg
Administration:	Oral adminstration
Result:	Inhibited NEFA expression as a dose-dependent manner.

Animal Model:	Guinea pigs
Dosage:	10 mg/kg
Administration:	Intravenous injection
Result:	Had the antilipolytic and flushing effects as a HCA2 agonist.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	SD rat
Dosage:	1, 30 and 100 mg/kg
Administration:	Oral adminstration
Result:	Inhibited NEFA expression as a dose-dependent manner.

Animal Model:	Guinea pigs
Dosage:	10 mg/kg
Administration:	Intravenous injection
Result:	Had the antilipolytic and flushing effects as a HCA2 agonist.

性状

Solid

溶解性数据

In Vitro:

DMSO : 16.67 mg/mL (64.94 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.8957 mL	19.4787 mL	38.9575 mL
5 mM	0.7791 mL	3.8957 mL	7.7915 mL
10 mM	0.3896 mL	1.9479 mL	3.8957 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 1.67 mg/mL (6.51 mM); Clear solution

此方案可获得 ≥ 1.67 mg/mL (6.51 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 16.7 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。